Publications by authors named "Jack Erion"

Claim this Profile
D
Dosimetry of [Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.
Lisa Bodei, Marta Cremonesi, Mahila Ferrari, Erik S Mittra, Harshad R Kulkarni, Jack L Erion

J Nucl Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-Dotatate: an analysis of the NETTER-1 study.
Jonathan Strosberg, Pamela L Kunz, Andrew Hendifar, James Yao, David Bushnell, Jack L Erion

Eur J Nucl Med Mol Imaging· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.
Jonathan Strosberg, Ghassan El-Haddad, Edward Wolin, Andrew Hendifar, James Yao, Jack L Erion

N Engl J Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Ebrahim S Delpassand, Amin Samarghandi, Sara Zamanian, Edward M Wolin, Mohammadali Hamiditabar, Jack L Erion

Pancreas· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.
Alida C Fröberg, Marion de Jong, Berthold A Nock, Wout A P Breeman, Jack L Erion

Eur J Nucl Med Mol Imaging· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
Gráinne B Biddlecombe, Buck E Rogers, Monique de Visser, Jesse J Parry, Marion de Jong, Jack L Erion

Bioconjug Chem· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors.
Paul J J M Janssen, Moniaue de Visser, Suzanne M Verwijnen, Bert F Bernard, Ananth Srinivasan, Jack L Erion

Cancer Biother Radiopharm· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia.
Rahul B Poria, Jeffrey P Norenberg, Tamara L Anderson, Jack Erion, Carston R Wagner

Cancer Biother Radiopharm· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer activity of targeted proapoptotic peptides.
Astrid Capello, Eric P Krenning, Bert F Bernard, Wout A P Breeman, Jack L Erion

J Nucl Med· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.
Bert Bernard, Astrid Capello, Martin van Hagen, Wout Breeman, Ananth Srinivasan, Jack Erion

Cancer Biother Radiopharm· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Wen Ping Li, Jason S Lewis, Joonyoung Kim, Joseph E Bugaj, Michael A Johnson, Jack L Erion

Bioconjug Chem· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Samuel Achilefu, Ananthacari Srinivasan, Michelle A Schmidt, Hermo N Jimenez, Joseph E Bugaj, Jack L Erion

J Med Chem· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
Wouter A P Breeman, Marion De Jong, Theo J Visser, Jack L Erion, Eric P Krenning

Eur J Nucl Med Mol Imaging· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Wouter A P Breeman, Katy van der Wansem, Bert F Bernard, Arthur van Gameren, Jack L Erion

Eur J Nucl Med Mol Imaging· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
Wouter A P Breeman, Marion de Jong, Jack L Erion, Joseph E Bugaj, Ananth Srinivasan

J Nucl Med· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents.
Samuel Achilefu, Hermo N Jimenez, Richard B Dorshow, Joseph E Bugaj, Elizabeth G Webb, Jack L Erion

J Med Chem· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis